Meeting
2020 Genitourinary Cancers Symposium
FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Katherine A. Zukotynski
Departments of Medicine and Radiology, McMaster University, Hamilton, ON, Canada
Katherine A. Zukotynski , Hossein Jadvar , Steve Y. Cho , Chun Ki Kim , Kathryn Cline , Urban Emmenegger , Sebastien J. Hotte , Gregory Russell Pond , Eric Winquist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Imaging
Clinical Trial Registration Number
NCT02813226
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 23)
Abstract #
23
Poster Bd #
A11
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Combining molecular and functional imaging in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Vincenza Conteduca
Poster
2022 ASCO Annual Meeting
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.
First Author: Kambiz Rahbar
Poster
2022 ASCO Genitourinary Cancers Symposium
PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.
First Author: A. Oliver Sartor
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi